Vistagen Therapeutics Inc [VTGN] stock is trading at $4.59, up 3.15%. An important factor to consider is whether the stock is rising or falling in short-term value. The VTGN shares have gain 20.79% over the last week, with a monthly amount glided 10.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vistagen Therapeutics Inc [NASDAQ: VTGN] stock has seen the most recent analyst activity on December 07, 2023, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $15 for it. Previously, Maxim Group upgraded its rating to Buy on August 07, 2023, and kept the price target unchanged to $30. On July 22, 2022, downgrade downgraded it’s rating to Mkt Perform. Robert W. Baird downgraded its rating to a Neutral. Jefferies downgraded its rating to a Hold. Robert W. Baird started tracking with an Outperform rating for this stock on May 20, 2021, and assigned it a price target of $9. In a note dated February 18, 2021, Jefferies initiated a Buy rating and provided a target price of $6 on this stock.
Vistagen Therapeutics Inc [VTGN] stock has fluctuated between $1.90 and $4.88 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Vistagen Therapeutics Inc [NASDAQ: VTGN] shares were valued at $4.59 at the most recent close of the market. An investor can expect a potential return of 161.44% based on the average VTGN price forecast.
Analyzing the VTGN fundamentals
Vistagen Therapeutics Inc [NASDAQ:VTGN] reported sales of 0.70M for the trailing twelve months, which represents a growth of 207.14%. Gross Profit Margin for this corporation currently stands at 0.41% with Operating Profit Margin at -90.81%, Pretax Profit Margin comes in at -86.32%, and Net Profit Margin reading is -86.32%. To continue investigating profitability, this company’s Return on Assets is posted at -0.77, Equity is -0.91 and Total Capital is -0.97. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.41 points at the first support level, and at 4.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.69, and for the 2nd resistance point, it is at 4.79.
Ratios To Look Out For
For context, Vistagen Therapeutics Inc’s Current Ratio is 5.79. On the other hand, the Quick Ratio is 5.79, and the Cash Ratio is 4.6. Considering the valuation of this stock, the price to sales ratio is 258.97, the price to book ratio is 2.69.
